Phuturdex › Diseases › Thrombocytopenia
Drugs in development · updated 30 October 2026
Thrombocytopenia: drugs in development
As of 30 October 2026 there are 24 active clinical trials (recruiting or ongoing, phases I–III) on 26 drugs for thrombocytopenia. 9 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Etamsylate | III | 1 | NCT07442513 |
| Mezagitamab | III | 1 | NCT06722235 |
| Hetrombopagherombopag | II | 2 | NCT07647029 |
| BT200 | II | 1 | NCT07273721 |
| Cyclic 14-day | II | 1 | NCT07647029 |
| Elritercept | II | 1 | NCT05037760 |
| Herombopag olamine tabletsHetrombopag Olamine | II | 1 | NCT07257809 |
| Recombinant human thrombopoietin | II | 1 | NCT06673498 |
| Telitacicept | II | 1 | NCT05998759 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AvatrombopagDoptelet Sprinkle®, Doptelet® | III | 2 | NCT07051915 |
| AzacitidineAzacytidine, 5-azacytidine | II–III | 1 | NCT05469737 |
| DexamethasoneDexametasone, Dextenza | II–III | 1 | NCT06913374 |
| RituximabRuxience, Rituxan | III | 1 | NCT07051915 |
| All-trans retinoic acidATRA, Tretinoin | II | 2 | NCT07586826 |
| EltrombopagRevolade, Eltrombopag Accord® | II | 2 | NCT04304820 |
| PacritinibVonjo® | II | 2 | NCT07447817 |
| RuxolitinibJakavi, Jakafi Xr® | II | 2 | NCT05980806 |
| SelinexorKPT-330, Xpovio® | II | 2 | NCT07447817 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | II | 1 | NCT04304820 |
| LuspaterceptACE-536, Reblozyl | II | 1 | NCT06788691 |
| LusutrombopagMulpleta®, Mulpleo (previously Lusutrombopag Shionogi)® | II | 1 | NCT06673498 |
| MomelotinibOjjaara®, Omjjara® | II | 1 | NCT05980806 |
| RomiplostimNplate | II | 1 | NCT07278661 |
| Tranexamic AcidTransexamic acid, Lysteda® | II | 1 | NCT06599762 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 26 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Autoimmune thrombocytopenic purpura 53 drugs
- Thrombotic Microangiopathies 6 drugs
- Atypical hemolytic uremic syndrome 5 drugs
- Systemic lupus erythematosus 178 drugs
- Evans' syndrome 3 drugs
- Autoimmune hemolytic anemia 13 drugs
- Neonatal alloimmune thrombocytopenia 3 drugs
- Myositis 42 drugs
- Autoimmune disease 94 drugs
- Antiphospholipid syndrome 6 drugs
- Behcet Syndrome 11 drugs
- Dermatomyositis 52 drugs
Broader categories
- Hematologic Diseases 57 drugs
- Cytopenia 14 drugs
- Bone marrow disease 14 drugs
- Neoplasm 671 drugs
- Immune System Diseases 54 drugs
- Myeloproliferative disorders 91 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D013921 “Thrombocytopenia”.